TB-500 is a synthetic version of thymosin beta-4, a peptide involved in cellular migration and repair. It is commonly studied for its potential to support healing, flexibility, and recovery.

TB-500 occupies a well-established position in preclinical regenerative biology research, with a mechanistic profile spanning actin dynamics, endothelial cell migration, angiogenesis, extracellular matrix remodeling, and inflammatory pathway modulation. What makes it particularly versatile as a tool compound is that these activities operate through at least two distinct molecular mechanisms — the intact peptide’s actin-binding and integrin αvβ3-mediated signaling activity, and the Ac-SDKP cleavage product’s NF-κB-dependent anti-inflammatory pathway engagement.

The intact TB-500 peptide drives VEGF-independent angiogenic signaling through integrin αvβ3 engagement and downstream Akt-eNOS pathway activation in endothelial preparations — a mechanism that remains active under VEGF-neutralized experimental conditions and is therefore pharmacologically separable from VEGF-dependent angiogenic tool compounds like BPC-157. This complementarity underlies the scientific rationale for studying TB-500 in multi-peptide combination research designs.

The Ac-SDKP tetrapeptide, released from the TB-500 N-terminus by renal meprin and prolyl oligopeptidase under physiological conditions, independently inhibits NF-κB-dependent pro-inflammatory gene expression in epithelial and renal cell preparations — establishing TB-500 as a dual-mechanism compound with both direct and cleavage-mediated bioactivity arms relevant to tissue remodeling and inflammatory pathway research.

• CAS Number: 77591-33-4
• Molecular Weight: ~4963 g/mol
• Purity: ≥99%
• Also Known As: Thymosin Beta-4, Tβ4, TB4, Ac-SDKP precursor peptide
• Chemical Formula: C₂₁₂H₃₅₀N₅₆O₇₈S

In cell-based and preclinical models, TB-500’s primary mechanism involves G-actin monomer sequestration through its LKKTETQ active domain. By binding free actin monomers, TB-500 regulates the ratio of monomeric to filamentous actin in cell preparations, facilitating cytoskeletal reorganization and directional cell migration in wound edge and scratch assay models. This actin-regulatory activity is central to TB-500’s role in cell motility research.

Angiogenic signaling operates through integrin αvβ3 receptor engagement and downstream Akt-eNOS pathway activation in endothelial cell preparations — a VEGF-independent route confirmed to remain functional under VEGF-blocking experimental conditions. This mechanistic independence from the VEGF axis distinguishes TB-500’s angiogenic activity from compounds like BPC-157 and makes it a complementary tool in dual-angiogenesis pathway research designs.

In cardiac tissue preparations, TB-500 exposure following ischemic injury models has been associated with enhanced angiogenesis, reduced fibrotic marker deposition in infarct border zone histology, and preserved ventricular function parameters — outcomes consistent with its combined actin-migration and endothelial signaling profile in tissue repair research models.

• Actin Dynamics and Cytoskeletal Reorganization Studies
• VEGF-Independent Angiogenesis and Integrin αvβ3 Signaling Research
• Cell Migration and Wound Edge Assay Models
• Ac-SDKP Cleavage and NF-κB Anti-Inflammatory Pathway Studies
• Cardiac and Tissue Repair Signaling Research
• Anti-Fibrotic Pathway and ECM Remodeling Models
• Multi-Peptide Combination and Angiogenic Pathway Complementarity Studies